Found the above on the Patia website as part of an announcement...

Found the above on the Patia website as part of an announcement regarding their upcoming presentation at the 2019 EASD conference (European Associate for the Study of Diabetes) http://www.patiadiabetes.com/en/patia-pioneering-t2d-and-gdm-prevention-and-intervention/

This conference is a nice platform to further market the commercialization into Europe.
The diabetic population is in excess of 50 Million across EUR.

I have been trying to do the math on what the potential revenue figure would like upon a successful global roll-out.
I think $10M p/a from royalties at $5 per test is quite achievable in the near term (1-5years). They mentioned test would sell for US$50 with royalties at 5-15%.

I recall seeing PIQ making claims of 100M+ in potential revenue, but I think that's a bit of hype but does have some substance given there are over 400 million people diagnosed with diabetes worldwide. Can you image, even at 10% penetration on the global market - we would be looking at revenues of $200M+.

I am sticking with my modest $10m near term which would give us a primitive valuation of at least $100-200million based on just the PromarkerD revenue alone.

Have a great weekend folks!